Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QTTB Stock Forecast 2025-2026
$3.32
Current Price
$40.85M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to QTTB Price Targets
+502.4%
To High Target of $20.00
+351.8%
To Median Target of $15.00
+201.2%
To Low Target of $10.00
QTTB Price Momentum
+51.6%
1 Week Change
+46.9%
1 Month Change
-87.2%
1 Year Change
-3.5%
Year-to-Date Change
-88.2%
From 52W High of $28.06
+146.8%
From 52W Low of $1.35
📊 TOP ANALYST CALLS
Did QTTB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Q32 Bio is one of their latest high-conviction picks.
Latest QTTB Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, QTTB has a neutral consensus with a median price target of $15.00 (ranging from $10.00 to $20.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $3.32, the median forecast implies a 351.8% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jay Olson at Oppenheimer, projecting a 502.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QTTB Analyst Ratings
1
Buy
1
Hold
0
Sell
QTTB Price Target Range
Low
$10.00
Average
$15.00
High
$20.00
Current: $3.32
Latest QTTB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QTTB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $15.00 |
| Feb 11, 2025 | Piper Sandler | Christopher Raymond | Neutral | Downgrade | $4.00 |
| Feb 11, 2025 | BMO Capital | Etzer Darout | Market Perform | Downgrade | $3.00 |
| Dec 12, 2024 | BMO Capital | Etzer Darout | Outperform | Maintains | $22.00 |
| Dec 12, 2024 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $N/A |
| Dec 11, 2024 | Leerink Partners | Thomas Smith | Market Perform | Downgrade | $9.00 |
| Dec 11, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $20.00 |
| Dec 11, 2024 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $20.00 |
| Dec 11, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $16.00 |
| Dec 11, 2024 | Raymond James | Steven Seedhouse | Outperform | Downgrade | $22.00 |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $64.00 |
| Oct 24, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Initiates | $90.00 |
| Sep 11, 2024 | Wells Fargo | Sarah Akers | Overweight | Initiates | $95.00 |
| Jun 17, 2024 | Guggenheim | Yatin Suneja | Buy | Initiates | $100.00 |
| May 21, 2024 | Leerink Partners | Thomas Smith | Outperform | Initiates | $54.00 |
| Apr 11, 2024 | Oppenheimer | Jay Olson | Outperform | Initiates | $50.00 |
| Apr 2, 2024 | Piper Sandler | Christopher Raymond | Overweight | Initiates | $45.00 |
Q32 Bio Inc. (QTTB) Competitors
The following stocks are similar to Q32 Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Q32 Bio Inc. (QTTB) Financial Data
Q32 Bio Inc. has a market capitalization of $40.85M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -841.1%.
Valuation Metrics
Market Cap
$40.85M
Enterprise Value
$11.91M
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+120.1%
Current Ratio
4.6x
Debt/Equity
-0.9x
ROE
-841.1%
ROA
-33.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Q32 Bio Inc. (QTTB) Business Model
About Q32 Bio Inc.
What They Do
Develops treatments for immune-mediated diseases.
Business Model
Q32 Bio Inc. operates by creating innovative biologic and small molecule therapies aimed at treating autoimmune and inflammatory diseases. The company generates revenue through the development and commercialization of its targeted therapeutics, addressing significant unmet medical needs in the healthcare market.
Additional Information
The company focuses on a diverse range of conditions affecting the immune system, including diseases relevant to dermatology, rheumatology, and gastroenterology. Q32 Bio is positioned as a key player in the biotech sector, contributing to advancements in precision medicine and tailored therapeutic strategies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
26
CEO
Ms. Jodie Pope Morrison
Country
United States
IPO Year
N/A
Website
www.q32bio.comQ32 Bio Inc. (QTTB) Latest News & Analysis
Latest News
Dow Dips 200 Points; Q32 Bio Shares Jump
5 days ago
Quick Summary
Q32 Bio Inc. (NASDAQ:QTTB) shares rose 171% to $5.91 following the sale of its Phase 2 drug ADX-097 to Akebia for $12 million, with potential payments up to $592 million.
Why It Matters
Q32 Bio's significant stock surge reflects investor optimism following a lucrative deal with Akebia, enhancing its financial position and potential future earnings.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Q32 Bio Inc. (NASDAQ: QTTB) shares are up on Monday, trading at a volume of 70.56 million, significantly higher than the average volume of 217.704 thousand.
Why It Matters
Increased trading volume for Q32 Bio Inc. signals heightened investor interest, potentially indicating a significant price movement or news catalyst, which can impact stock valuation.
Source: Benzinga
Market Sentiment:
Positive
Q32 Bio Sells Complement Inhibitor ADX-097
6 days ago
Quick Summary
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia, securing $12 million upfront and potential total payments of $592 million. This supports its focus on bempikibart for alopecia areata.
Why It Matters
The asset sale strengthens Q32 Bio's focus on its alopecia areata treatment, extends its cash runway, and opens potential for significant milestone and royalty payments, enhancing its investment appeal.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio completed enrollment in Part B of its SIGNAL-AA Phase 2a trial, increasing the size to 33 patients, with data expected in mid-2026. The company has $49M in cash, funding into 2027.
Why It Matters
Q32 Bio's trial progress and financial stability indicate potential for future growth and innovation in treating alopecia areata, attracting investor interest in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio completed enrollment in Part B of its SIGNAL-AA Phase 2a trial for bempikibart, increasing the trial size to 33 patients due to high demand.
Why It Matters
Successful enrollment in the SIGNAL-AA trial indicates strong demand and potential efficacy for bempikibart, which could enhance Q32 Bio's market position and attract investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio Inc. (Nasdaq: QTTB) will participate in a fireside chat on August 28, 2025, discussing its focus on therapies for alopecia areata and other autoimmune diseases.
Why It Matters
Q32 Bio's participation in a fireside chat may signal potential developments or insights into their pipeline, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About QTTB Stock
What is Q32 Bio Inc.'s (QTTB) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Q32 Bio Inc. (QTTB) has a median price target of $15.00. The highest price target is $20.00 and the lowest is $10.00.
Is QTTB stock a good investment in 2026?
According to current analyst ratings, QTTB has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QTTB stock?
Wall Street analysts predict QTTB stock could reach $15.00 in the next 12 months. This represents a 351.8% increase from the current price of $3.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Q32 Bio Inc.'s business model?
Q32 Bio Inc. operates by creating innovative biologic and small molecule therapies aimed at treating autoimmune and inflammatory diseases. The company generates revenue through the development and commercialization of its targeted therapeutics, addressing significant unmet medical needs in the healthcare market.
What is the highest forecasted price for QTTB Q32 Bio Inc.?
The highest price target for QTTB is $20.00 from Jay Olson at Oppenheimer, which represents a 502.4% increase from the current price of $3.32.
What is the lowest forecasted price for QTTB Q32 Bio Inc.?
The lowest price target for QTTB is $10.00 from at , which represents a 201.2% increase from the current price of $3.32.
What is the overall QTTB consensus from analysts for Q32 Bio Inc.?
The overall analyst consensus for QTTB is neutral. Out of 8 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are QTTB stock price projections?
Stock price projections, including those for Q32 Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 2:58 AM UTC